Hidden gut issue in Crohn's patients under the microscope
NCT ID NCT03915262
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how common exocrine pancreatic insufficiency (EPI) is in people with active Crohn's disease who are starting a biologic therapy. EPI means the pancreas doesn't make enough enzymes to digest food properly. Researchers will check for EPI at the start of treatment and again 14 weeks later. The goal is to better understand this condition in Crohn's patients and how it changes with treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Service d'Hépato-Gastroentérologie, Centre Hospitalier Lyon-Sud, HCL
RECRUITINGPierre-Bénite, 69495, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a patient registry unlock the secrets of IBD?
- Can we predict how kids with IBD will respond to treatment?
- Can switching IBD meds heal the gut when symptoms are quiet?
- Can a milk sugar tame IBD symptoms?
- Could an extra flu shot shield vulnerable kids?
- Can a Real-World study reveal the staying power of guselkumab?